Elanco Animal Health Executive Compensation Details
Ticker: ELAN · Form: DEF 14A · Filed: 2025-03-27T00:00:00.000Z
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Elanco's 2025 DEF 14A is out, showing exec comp details for 2024. Focus on equity awards for PEOs and non-PEOs.
AI Summary
Elanco Animal Health Inc. filed its DEF 14A on March 27, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to both principal executive officers (PEO) and non-PEO/NEO members, as well as changes in the fair value of outstanding and unvested equity awards.
Why It Matters
This filing provides transparency into how Elanco Animal Health compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine annual filing providing information on executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 2024 — Fiscal Year (Compensation details are for this year.)
- 20250327 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- Elanco Animal Health Inc (company) — Filer of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
- 20250327 (date) — Filing date of the DEF 14A
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders for an upcoming annual meeting or special meeting of shareholders. It contains detailed information about matters to be voted on, including director elections, executive compensation, and other corporate governance issues.
Who are the Principal Executive Officers (PEO) and Non-PEO/NEO members mentioned in the filing?
The filing refers to equity awards granted to 'PeoMember' (Principal Executive Officer members) and 'NonPeoNeoMember' (Non-Principal Executive Officer/Named Executive Officer members), indicating compensation structures for different tiers of company leadership.
What specific types of equity awards are detailed in the filing?
The filing details 'EqtyAwrdsInSummryCompstnTblForAplblYrMember' (Equity Awards in Summary Compensation Table for Applicable Year Member), 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' (Year-End Fair Value of Equity Awards Granted in Covered Year Outstanding and Unvested Member), and 'ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember' (Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years Member).
What is the significance of the 'ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember' metric?
This metric refers to the change in the fair value as of the vesting date of prior year equity awards that vested in the covered year, providing insight into the performance of previously granted awards.
When is Elanco Animal Health's fiscal year end?
Elanco Animal Health's fiscal year ends on December 31st, as indicated by the reporting periods for which compensation data is presented.
From the Filing
0001739104-25-000030.txt : 20250327 0001739104-25-000030.hdr.sgml : 20250327 20250327122158 ACCESSION NUMBER: 0001739104-25-000030 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20250516 FILED AS OF DATE: 20250327 DATE AS OF CHANGE: 20250327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 25777883 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 DEF 14A 1 elan-20250327.htm DEF 14A elan-20250327 0001739104 DEF 14A false iso4217:USD 0001739104 2024-01-01 2024-12-31 0001739104 2023-01-01 2023-12-31 0001739104 2022-01-01 2022-12-31 0001739104 2021-01-01 2021-12-31 0001739104 2020-01-01 2020-12-31 0001739104 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001739104 ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001739104 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001739104 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001739104 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0001739104 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001739104 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001739104 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001739104 1 2024-01-01 2024-12-31 0001739104 2 2024-01-01 2024-12-31 0001739104 3 2024-01-01 2024-12-31 0001739104 4 2024-01-01 2024-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 Elanco Animal Health Inc orporated (Name of registrant as specified in its charter) (Name of person(s) filing proxy statement, if other than the registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. Letter from our Leadership Dear Shareholders, Elanco Animal Health delivered a strong year with increasing momentum as we head into 2025. With a concentrated focus on high-impact opportunities, Elanco delivered organic constant currency revenue growth in each quarter of 2024, driven by our diverse portfolio of innovative products, including one new blockbuster and five additional potential blockbusters now on the market. With momentum behind our portfolio, we delivered $461 million in innovation revenue, exceeding our 2024 target, and we expect these new products to continue to make meaningful contributions in the coming years. In addition to a growing innovation portfolio, we experienced growth in all five of our top product franchises and nine of our top ten countries, demonstrating stabilization in our base business. With the divestiture of the aqua business, Elanco sharpened our strategic focus and strengthened our company-wide focus on disciplined capital manage